BLUEBIRD BIO, INC. |
Market Closed -
Other stock markets
|
After market 00:57:36 | |||
| 1.02 USD | -3.77% |
|
1.01 | -0.98% |
| 05-09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| 05-06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
Presenter SpeechElizabeth Pingpank (Executives)All right. Good evening, everyone, and welcome ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
1.02
USD
Average target price
4.062
USD
Spread / Average Target
+298.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.09% | 197M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.21% | 21.93B | |
| -12.15% | 22.34B | |
| -5.52% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Transcript : bluebird bio, Inc. - Shareholder/Analyst Call
